HDAC9-IN-1
Based on 1 Customer Validation
HDAC9-IN-1 is a selective class IIa HDAC inhibitor that binds to HDAC9 with an IC50 of 40 nM. HDAC9-IN-1 potently inhibits HDACs 4 and 7 while showing weak activity against HDAC6 (IC50 values: 180 nM (HDAC4), 190 nM (HDAC7), 970 nM (HDAC6)). HDAC9-IN-1 significantly inhibits several human cancer cells, induces apoptosis and DNA damage in human cancer cells, and modulates caspase-related proteins and p38 in human cancer cells. HDAC9-IN-1 can be used for the research of oral cancer, breast cancer, gastric cancer.
For research use only. We do not sell to patients.
- Purity : 95.13%
- Formula: C27H22N4O3S
- Molecular Weight:482.55
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
[1]|
HDAC9 40 nM (IC50) |
HDAC4 180 nM (IC50) |
HDAC7 190 nM (IC50) |
HDAC6 970 nM (IC50) |
Caspase-8 |
Caspase-9 |
In Vitro
HDAC9-IN-1 (compound 7g) (5-30 min) potently inhibits HDAC 9 and class IIa HDACs 4 and 7 while showing weak activity against HDAC 6 and no activity against class I HDACs (IC50 values: 40 nM (HDAC9), 180 nM (HDAC4), 190 nM (HDAC7), 970 nM (HDAC6), >40 μM (class I))[1].
HDAC9-IN-1 (24 h) inhibits viability of cancer cells and normal lung fibroblasts (IC50 values: 3.0 μM (SCC2095), 8.4 μM (MDA-MB-231), 5.8 μM (SCM-1), 8.0 μM (normal lung fibroblasts))[1].
HDAC9-IN-1 (1-10 μM; 24-48 h) induces dose- and time-dependent apoptosis in SCC2095 cells[1].
HDAC9-IN-1 (1-10 μM; 24 h) modulates apoptotic, HDAC substrate, and stress response proteins in SCC2095 cells[1].
HDAC9-IN-1 (2.5-5 μM; 12-24 h) increases ROS generation accompanied by the increased DNA damage in SCC2095 cells in a time-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Human oral cancer SCC2095 cells
-
Concentration:1 μM, 2.5 μM, 5 μM, 7.5 μM, and 10 μM
-
Incubation Time:24 h, 48 h
-
Result:Induced apoptosis in a dose- and time-dependent manner: 10 μM for 24 h increased apoptotic cells to 83.6%; 1, 2.5, 5, 7.5, 10 μM for 48 h resulted in apoptosis rates of 29.2%, 35.9%, 44.4%, 78.2%, and 87.1%, respectively.
-
Cell Line:SCC2095 cells
-
Concentration:1 μM, 2.5 μM, 5 μM, 7.5 μM, and 10 μM
-
Incubation Time:24 h
-
Result:Down-regulated the levels of pro-caspase 8 and up-regulated the levels of cleaved caspase 9.
The levels of HDAC6 substrates such as acetyl-α-tubulin and Hsp90, and two class IIa HDAC-related proteins including
PPARγ and p21 were increased.
Up-regulated the phosphorylation of p38 in a dose-dependent manner in SCC2095 cells.
Increased the phosphorylation of Histone H2A.X, a DNS damage biomarker.
Chemical Information
-
Appearance Solid
-
Molecular Weight 482.55
-
Formula C27H22N4O3S
-
Color Light brown to brown
-
SMILES
N/C(C1=CC2=C(SC3=CC=CC=C3N2CC4=CC=C(C(C5=CC=CC=C5)=C4)C(NO)=O)C=C1)=N\O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (103.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Purity & Documentation
-
Data Sheet (286 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0723 mL | 10.3616 mL | 20.7232 mL | 51.8081 mL |
| 5 mM | 0.4145 mL | 2.0723 mL | 4.1446 mL | 10.3616 mL | |
| 10 mM | 0.2072 mL | 1.0362 mL | 2.0723 mL | 5.1808 mL | |
| 15 mM | 0.1382 mL | 0.6908 mL | 1.3815 mL | 3.4539 mL | |
| 20 mM | 0.1036 mL | 0.5181 mL | 1.0362 mL | 2.5904 mL | |
| 25 mM | 0.0829 mL | 0.4145 mL | 0.8289 mL | 2.0723 mL | |
| 30 mM | 0.0691 mL | 0.3454 mL | 0.6908 mL | 1.7269 mL | |
| 40 mM | 0.0518 mL | 0.2590 mL | 0.5181 mL | 1.2952 mL | |
| 50 mM | 0.0414 mL | 0.2072 mL | 0.4145 mL | 1.0362 mL | |
| 60 mM | 0.0345 mL | 0.1727 mL | 0.3454 mL | 0.8635 mL | |
| 80 mM | 0.0259 mL | 0.1295 mL | 0.2590 mL | 0.6476 mL | |
| 100 mM | 0.0207 mL | 0.1036 mL | 0.2072 mL | 0.5181 mL |
Keywords
- HDAC9-IN-1
- HDAC
- DNA/RNA Synthesis
- Reactive Oxygen Species (ROS)
- Apoptosis
- Caspase
- p38 MAPK
- caspase-related proteins
- HDAC9
- normal lung fibroblasts
- MDA-MB-231
- ROS generation
- class IIa HDACs
- apoptosis
- HDAC4
- breast cancer
- molecular modelling
- HDAC6
- class I HDACs
- SCC2095
- p38
- SCM-1
- class IIa HDAC inhibitor
- HDAC7
- human cancer cells
- gastric cancer
- DNA damage
- oral cancer
- Inhibitor
- inhibitor
- inhibit